drugset / Trial / NCT00711620

Efficacy of Thymosin alpha1 for Severe Sepsis

NCT00711620

Completed 366 enrolled Sun Yat-sen University
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.

Timeline

Start
2008-05
Primary completion
2010-12
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymalfasin Peptide 1.6 mg Subcutaneous